LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aktien・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Geschlossen

BrancheGesundheitswesen

1.12 -7.44

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.12

Max

1.1400000000000001

Schlüsselkennzahlen
By Trading Economics
Einkommen	32M -8.3M
Verkäufe	-7.5M 37M
EPS	-0.12
Gewinnspanne	-22.258
Angestellte	485
EBITDA	509K -38M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+112.5% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-60M 421M
Vorheriger Eröffnungskurs	8.56
Vorheriger Schlusskurs	1.12

Nachrichtenstimmung

By Acuity

64%

36%

283 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

1.13 / N/A Unterstützung & Widerstand

Pacific Biosciences of California Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Pacific Biosciences of California Inc Prognose

Kursziel

By TipRanks

112.5% Vorteil

12-Monats-Prognose

Durchschnitt 2.38 USD 112.5%

Hoch 3 USD

Tief 1.5 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pacific Biosciences of California Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pacific Biosciences of California Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.13 / N/AUnterstützung & Widerstand

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Stimmung

By Acuity

283 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.